The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease

References

• Lopez AD, Murray CJL. The global burden of disease, 1990–2020. Nat. Med.4, 1241–1243 (1998).
   PubMed Web of Science ®Google Scholar
• Murray CLJ, Lopez AD. Evidence-based health policy: lessons from the global burden of disease study. Science274, 740–743 (1996).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Lee A, Towse L et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 58(10), 855–860 (2003).
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J.19, 217–224 (2002).
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur. Respir. J.19, 209–216 (2002).
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax58(5), 399–404 (2003).
   PubMed Web of Science ®Google Scholar
• Celli B, ZuWallack R, Wang S et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest124(5), 1743–1748 (2003).
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur. Respir. J.23(6), 832–840 (2004).
   PubMed Web of Science ®Google Scholar
• Maltais F, Hamilton A, Marciniuk D et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest128(3), 1168–1178 (2005).
   PubMed Web of Science ®Google Scholar
• Verkindre C, Bart F, Aguilaniu B et al. The Effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration73(4), 420–427 (2006).
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med.143(5), 317–326 (2005).
   PubMed Web of Science ®Google Scholar
• Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J.27(3), 547–555 (2006).
   PubMed Web of Science ®Google Scholar
• Haughney J, Partridge MR, Vogelmeier C et al. Exacerbations of COPD: quantifying the patient’s perspective using discrete choice modelling. Eur. Respir. J.26(4), 623–629 (2005).
   PubMed Web of Science ®Google Scholar
• Tashkin D, Celli B, Decramer M et al. Regional patterns in the characteristics of patients recruited into a long-term global clinical trial in COPD (UPLIFT). Proc. Am. Thorac. Soc2(Abstract Issue), A412 (2005).
   Google Scholar
• Spencer S, Calverley PMA, Burge PS et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.163(1), 122–128 (2001).
   PubMed Web of Science ®Google Scholar
• Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis.145(2 Pt 1), 467–470 (1992).
   PubMed Web of Science ®Google Scholar
• Heijdra YF, Pinto-Plata VM, Kenney LA et al. Cough and phlegm are important predictors of health status in smokers without COPD. Chest121(5), 1427–1433 (2002).
   PubMed Web of Science ®Google Scholar
• Wegner RE, Jorres RA, Kirsten DK et al. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur. Respir. J.7(4), 725–729 (1994).
   PubMed Web of Science ®Google Scholar
• McCathie HC, Spence SH, Tate RL. Adjustment to chronic obstructive pulmonary disease: the importance of psychological factors. Eur. Respir. J.19(1), 47–53 (2002).
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory Questionnaire. Am. Rev. Respir. Dis.145, 1321–1327 (1992).
   PubMed Web of Science ®Google Scholar
• Domingo-Salvany A, Lamarca R, Ferrer M et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.166(5), 680–685 (2002).
   PubMed Web of Science ®Google Scholar
• Seemungal TAR, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.157(5), 1418–1422 (1998).
   PubMed Web of Science ®Google Scholar
• Vega Reyes JA, Montero Perez-Barquero M, Sanchez GP. Assessing COPD-associated morbidity: factors of prognosis. Med. Clin. (Barc.)122(8), 293–297 (2004).
   Google Scholar
• Osman LM, Godden DJ, Friend JA et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax52(1), 67–71 (1997).
   PubMed Web of Science ®Google Scholar
• ZuWallack R. Clinical interpretation of health-related quality of life outcomes in COPD: application to clinical care. Eur. Respir. Rev.12(83), 92–97 (2002).
   Google Scholar
• Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur. Respir. J. Suppl.41, S36–S45 (2003).
   Google Scholar
• Wyrwich KW, Tierney WM, Babu AN et al. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv. Res.40(2), 577–591 (2005).
   PubMed Web of Science ®Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care41(5), 582–592 (2003).
   PubMed Web of Science ®Google Scholar
• Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur. Respir. J.19, 398–404 (2002).
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Juniper EF, Walter SD et al. Interpreting treatment effects in randomised trials. Br. Med. J.316(7132), 690–693 (1998).
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): 1. Conceptual framework and item selection. Med. Care30(6), 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. Br. Med. J.306(6890), 1437–1440 (1993).
   PubMed Web of Science ®Google Scholar
• Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition). Spilker B (Ed.). Lippincott-Raven Publishers, PA, USA, 191–201 (1996)
   Google Scholar
• Rutten-van Molken M, Oostenbrink JB, Monz BU. EQ-5D discriminates between COPD patients of different severity. Eur. Respir. J. Suppl26(Suppl. 49), S470–S470 (2005).
   Google Scholar
• Stahl E, Lindberg A, Jansson SA et al. Health-related quality of life is related to COPD disease severity. Health Qual. Life Outcomes3, 56 (2005).
   PubMedGoogle Scholar
• Brooks R. The measurement and validation of health status using EQ-5D: a European perspective. In: Evidence From the EuroQol BIO MED Research Programme. Brooks R, Rabin R, de Charro F (Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands, 303 (2003).
   Google Scholar
• Jones PW. Overview of health-related quality of life outcomes in pivotal tiotropium trials. Eur. Respir. Rev.12(83), 73–75 (2002).
   Google Scholar
• Schunemann HJ, Griffith L, Jaeschke R et al. Evaluation of the minimal important difference for the feeling thermometer and the St. George’s Respiratory Questionnaire in patients with chronic airflow obstruction. J. Clin. Epidemiol.56(12), 1170–1176 (2003).
   PubMed Web of Science ®Google Scholar
• Meguro M, Jones PW. Validation of a shorter version of the SGRQ specifically for COPD. Proc. Am. Thorac. Soc.2(Abstract Issue), A386 (2005).
   Google Scholar
• Lindsay M, Lee A, Chan K et al. Does pulmonary rehabilitation give additional benefit over tiotropium therapy in primary care management of chronic obstructive pulmonary disease? Randomized controlled clinical trial in Hong Kong Chinese. J. Clin. Pharm. Ther.30(6), 567–573 (2005).
   Google Scholar
• Schunemann HJ, Puhan MA, Goldstein R et al. Measurement properties and interpretability of the Chronic Respiratory Disease Questionnaire (CRQ). COPD: J. Chronic Obstructive Pulmonary Dis.2(1), 81–89 (2005).
   Google Scholar
• Wijkstra PJ, TenVergert EM, Van Altena R et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax49(5), 465–467 (1994).
   PubMed Web of Science ®Google Scholar
• Schunemann HJ, Guyatt GH, Griffith L et al. A randomized controlled trial to evaluate the effect of informing patients about their pretreatment responses to two respiratory questionnaires. Chest122(5), 1701–1708 (2002).
   Google Scholar
• Puhan MA, Behnke M, Frey M et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual. Life Outcomes2(1), 1 (2004).
   PubMedGoogle Scholar
• van der Molen T, Willemse BWM, Schokker S et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life OutcomesI(13), 1–10 (2003).
   Google Scholar
• Damato S, Bonatti C, Frigo V et al. Validation of the Clinical COPD questionnaire in Italian language. Health Qual. Life Outcomes3(1), 9 (2005).
   PubMedGoogle Scholar
• Stallberg B, Nokela M, Ehrs P-O et al. Validation of the clinical COPD questionnaire (CCQ) in Swedish primary care. Eur. Respir. J.26(Suppl. 49), S671 (2005).
   Google Scholar
• Tonnel AB, Perez T, Grosbois JM et al. Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice. Eur. Respir. J.26(Suppl 49), 290s (2005).
   Google Scholar
• Tonnel A-B, Bravo M-L, Brun M. Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study. Proc. Am. Thorac. Soc2(Abstract Issue), A540 (2005).
   Google Scholar
• Tonnel A-B, Perez T, Grosbois JM et al. Psychometric validation of the Visual Simplified Respiratory Questionnaire (VSRQ) in France for chronic obstructive pulmonary disease (COPD). Eur. Respir. J.26(Suppl. 49), S512 (2005).
   Google Scholar
• Disse B, Witek TJJ. Anticholinergics: tiotropium. In: New Drugs for Asthma, Allergy and COPD. Prog. Respir. Res. (31). Hansel TT, Barnes PJ (Eds). Karger, Basle, Switzerland, 72–76 (2001).
   Google Scholar
• Barnes PJ. Tiotropium bromide. Expert Opin. Investig. Drugs10(4), 733–740 (2001).
   PubMed Web of Science ®Google Scholar
• Turino GM. Therapeutic gains of prolonged bronchial dilatation in chronic obstructive pulmonary disease. Ann. Intern. Med.143(5), 386–387 (2005).
   Google Scholar
• Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest122, 47–55 (2002).
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Revill S, Webb KA. Dynamic hyperinflation (DH) during exercise in COPD: physiological correlates. Am. J. Respir. Crit. Care Med.163, A269 (2001).
   Google Scholar
• Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest127(3), 809–817 (2005).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Kesten S. Effects of tiotropium in COPD patients only treated with PRN albuterol. Am. J. Respir. Crit. Care Med.169(Suppl.), A611 (2004).
   Google Scholar
• Spencer S, Jones PW for the Tiotropium Study Group. Decline in health status over one year is eliminated by tiotropium. Am. J. Respir. Crit. Care Med.165(8), A228 (2002).
   Google Scholar
• Troosters T, Casaburi R, Gosselink R et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.172(1), 19–38 (2005).
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PMA, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J.320, 1297–1303 (2000).
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Lam MIU, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.160(2), 542–549 (1999).
   PubMed Web of Science ®Google Scholar
• Verkindre C, Bart F, Aguilaniu B et al. The effect of tiotropium on hyperinflation and exercise capacity in COPD. Respiration73(4), 420–427 (2005).
   Google Scholar
• Barr RG, Bourbeau J, Camargo CA et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2), CD002876 (2005).
   Google Scholar
• Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD: J. Chronic Obstructive Pulmonary Dis.1(2), 303–312 (2004).
   Google Scholar
• Brusasco V, Thompson P, Vincken W et al. Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. Eur. Respir. J.18(33), S26 (2001).
   Google Scholar
• O’Donnell DE, Voduc N, Fitzpatrick M et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J.24(1), 86–94 (2004).
   PubMed Web of Science ®Google Scholar
• Liesker JJ, Van De Velde V, Meysman M et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir. Med.96(8), 559–566 (2002).
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M et al. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest123(6), 1810–1816 (2003).
   Google Scholar
• Garcia Ruiz AJ, Leiva FF, Martos CF. Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol. Arch. Bronconeumol.41(5), 242–248 (2005).
   Google Scholar
• Oostenbrink JB, Rutten-van Mölken MP, van Noord JA et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur. Respir. J.23(2), 241–249 (2004).
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Molken MP, Monz BU et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health8(1), 32–46 (2005).
   PubMed Web of Science ®Google Scholar
• Schramm W, Haake D, Brandt A. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Schweiz. Rundsch. Med. Prax.94(46), 1803–1810 (2005).
   Google Scholar
• van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J.26(2), 214–222 (2005).
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest129(3), 509–517 (2006).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Timmer W, Sagriotis A et al. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Eur. Respir. J.26(Suppl. 49), S14 (2005).
   Google Scholar
• van Noord JA, Smeets JJ, Otte A et al. The effect of tiotropium, salmeterol and its combination on dynamic hyperinflation in COPD. Proc. Am. Thorac. Soc2(Abstract Issue), A542 (2005).
   Google Scholar
• Vestbo J. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur. Respir. J.24(2), 206–210 (2004).
   PubMed Web of Science ®Google Scholar
• Dalby R, Spallek M, Voshaar T. A review of the development of Respimat soft mist inhaler. Int. J. Pharm.283(1–2), 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J. Clin. Epidemiol.47(1), 81–87 (1994).
   PubMed Web of Science ®Google Scholar